UnitedHealth downgraded, Home Depot upgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top Upgrades:
Stifel upgraded Home Depot (HD) to Buy from Hold with a price target of $425, up from $405, following the Q1 report. The firm is surprised the shares didn't rally post earnings, with accelerating comparable sales through fiscal Q1 "the key positive takeaway," with April U.S. comparable sales up nearly 2.5%.
BofA upgraded AutoZone (AZO) to Buy from Neutral with a price target of $4,800, up from $3,900, to reflect increasing confidence in the company's recession resilient history, ongoing share gains, potential inflation benefit from price increases, potentially more favorable dynamics in used versus new car sales and continued tailwinds from maturing commercial programs.
HSBC upgraded Bilibili (BILI) to Buy from Hold with a price target of $22.50, up from $21.50. The firm has turned more constructive on the soon to launch S8 at the end of May, which it says contains major updates to game play, maps and characters as the game celebrates its one-year anniversary.
Deutsche Bank upgraded Acadia Pharmaceuticals (ACAD) to Buy from Hold with a price target of $35, up from $20. The firm now sees an attractive setup ahead of the Phase 3 data in Prader Willi syndrome in early Q4.
Northland upgraded Evolv (EVLV) to Outperform from Market Perform with a $7.50 price target after Evolv held its first earnings call with its new CEO and CFO following the company's restatements.
Top Downgrades:
HSBC downgraded UnitedHealth (UNH) to Reduce from Hold with a price target of $270, down from $490. The company's CEO change, the pulled 2025 guidance, and alleged Medicare fraud have resulted in its market cap halving since the Q1 results, the firm tells investors in a research note.
Scotiabank downgraded Myriad Genetics (MYGN) to Sector Perform from Outperform with a price target of $6, down from $20. While the firm continues to believe there is opportunity for Myriad to execute against its Oncology and Women's Health business ambitions over the next several years, 2025 is likely to be "a transitional year," the firm tells investors in a research note.
More bearish on the stock, Compass Point downgraded PennantPark (PNNT) to Sell from Neutral with a price target of $5.75, down from $6.
RBC Capital downgraded CAE (CAE) to Sector Perform from Outperform with a price target of C$38, down from C$41. The shares trade the most expensive in the sector, making the solid long-term trends in pilot training and defense spending appropriately reflected at current levels, the firm tells investors in a research note.
Top Initiations:
Deutsche Bank resumed coverage of Intel (INTC) with a Hold rating and $23 price target. The firm has confidence in new CEO Lip-Bu Tan's ability to formulate a transformation strategy that can reaccelerate "profitable and sustainable growth," but says the execution of this strategy and eventual achievement "will likely be challenging and time consuming."
Jefferies initiated coverage of SelectQuote (SLQT) with a Hold rating and $2.75 price target. The firm says SelectRx's strategic redirect to even higher acuity members, the recent Department of Justice lawsuit, "suboptimal" cash conversion, and a "complicated balance sheet" keep it on the sidelines.
Stifel initiated coverage of Atlas Energy (AESI) with a Buy rating and $15 price target. The firm says its positive view is based on the company's "high-quality, low cost" mines, low-cost delivery system, including its proprietary Dune Express, and growth opportunities provided by Atlas Energy's recently acquired power generation business Moser.
Oppenheimer initiated coverage of Tvardi Therapeutics (TVRD) with an Outperform rating and $65 price target. The firm sees an "underappreciated opportunity" for the company's lead asset TTI-101, a first-in-class STAT3 inhibitor, in idiopathic pulmonary fibrosis and hepatocellular carcinoma.
William Blair initiated coverage of Lifecore (LFCR) with an Outperform rating. Minimum volume commitments from Alcon (ALC) represent "a solid foundation for Lifecore's achievable midterm revenue guide," says the firm, which projects revenue will grow at an 11.6% compound annual rate from FY25 to FY28, consistent with Lifecore's guidance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
This FTSE 100 bank is up 60% in year but still cheap with a P/E of just 9!
This FTSE 100 bank has had a storming run. Its share price is up 60% in the last 12 months, and 170% over five years. The company in question is Standard Chartered (LSE: STAN), and to my irritation, I've paid very little attention to it. I'm all over Barclays, Lloyds, HSBC and NatWest. My interest is no doubt boosted by the fact they have a UK high street presence. Standard Chartered doesn't. Despite being headquartered in the UK, it doesn't offer retail banking here. Instead, around 90% of profits come from Asia, Africa and the Middle East, which gives it access to a far bigger, faster-growing target market. For those seeking international exposure, it's easy to overlook in favour of HSBC, which does both, and has a far larger market cap at £152bn, compared to £27bn. But none of that has held the Standard Chartered share price back lately. Full-year results, published on 27 February, were impressive. Pre-tax profit for 2024 jumped almost 18% from $5.1bn to $6bn year-on-year. Operating income climbed 14% to $19.7bn, with a record performance in the wealth division. Global markets and global banking also delivered double-digit growth. The net interest margin edged up to 1.94%, and the bank said it attracted 265,000 new affluent clients, bringing in $44bn of new money. That's a 61% year-on-year increase. Management treated shareholders to a $1.5bn share buyback. Momentum continued into the first quarter of 2025, with results published on 2 May showing pre-tax profits up again, to $2.1bn. The group stuck to its medium-term forecast of 5%-7% annual income growth through to 2026. While the outlook is encouraging, no bank is risk-free. One concern is geopolitics. Standard Chartered's deep exposure to Asia, and China in particular, leaves it vulnerable to worsening trade tensions with the US. Management has warned that protectionist policies and tariffs could hit global growth and weigh on client activity. The second issue is exposure to unsecured consumer borrowing. Credit impairment charges rose 24% in Q1, mostly due to rising stress in parts of the wealth and retail banking division. That's a red flag if interest rates stay high for longer. A final concern is that the recent share price rally may be overdone. Analyst forecasts now suggest limited short-term growth from here, with a consensus one-year target of 1,224p. That would be just 2.5% above today's level. Despite the recent surge, Standard Chartered's price-to-earnings ratio is just 9.24. That compares favourably to HSBC at 9.32, NatWest at 9.75, and Barclays at 8.88. Its dividend yield is relatively modest, at 2.34%. But don't be misled. The 2024 total payout was hiked 37%, from 27 US cents per share to 37 cents. I'm tempted, but I think I'll stick to Lloyds, which I hold. It lacks the international growth of an Asia listing but also ducks the risks. But I'll be keeping a closer eye on Standard Chartered from now on. The post This FTSE 100 bank is up 60% in year but still cheap with a P/E of just 9! appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool HSBC Holdings is an advertising partner of Motley Fool Money. Harvey Jones has positions in Lloyds Banking Group Plc. The Motley Fool UK has recommended Barclays Plc, HSBC Holdings, Lloyds Banking Group Plc, and Standard Chartered Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 hours ago
- Yahoo
This Under-the-Radar Healthcare Stock Could Be a Solid Income Play
CVS Health Corporation (NYSE:CVS) is one of the best dividend stocks for a bear market. Even during economic downturns, people continue to rely on medications, essential consumer products, and affordable local healthcare. CVS Health Corporation (NYSE:CVS) serves as a convenient healthcare and retail destination within communities. A row of shelves in a retail pharmacy, demonstrating the variety of drugs and over-the-counter products. The company's overall business remains solid, thanks to its diversified operations and multiple sources of revenue. In recent years, it has expanded its presence in primary care and launched a subsidiary called Cordavis to focus on developing and marketing biosimilar drugs. Its broad reach across communities and wide range of services are key advantages. Lately, higher Medicare usage and increased post-pandemic healthcare costs have impacted the company's revenue and earnings growth. However, CVS Health Corporation (NYSE:CVS) remains profitable and maintains a solid cash position. In the most recent quarter, it reported $4.6 billion in operating cash flow. Looking ahead to 2025, the company has raised its full-year operating cash flow forecast from around $6.5 billion to approximately $7.0 billion. In addition, CVS Health Corporation (NYSE:CVS) appears to have significant room to grow its dividend. With a cash payout ratio of just 30%, even doubling that figure would still leave it within a sustainable range. Due to this strong cash generation, CVS Health Corporation (NYSE:CVS) has maintained its payouts since 1997. Currently, it offers a quarterly dividend of $0.665 per share and has a dividend yield of 3.96%, as of June 17. While we acknowledge the potential of CVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
Yahoo
15 hours ago
- Yahoo
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an 'Overweight' rating on the stock with a $145 price target. The bullish stance follows positive discussions with a European specialist on the company's VYKAT XR medication for Prader-Willi syndrome (PWS). A scientist in a laboratory examining a microscope in the pursuit of cell therapy discoveries. Piper Sandler consulted a UK-based pediatric endocrinologist to understand the drug better. The specialist indicated she would prescribe the drug as medication for Prader-Willi syndrome (PWS) to all eligible patients upon approval. Soleno Therapeutics' edge with the drug stems from the fact that other PWS treatments are in the early stages of development. Piper Sandler believes VYKAT XT represents significant potential as the first approved treatment specifically addressing PWS, a condition. The biotech company plans to file a Marketing Authorization Application for VYKAT XR in the second quarter. It's also pursuing regulatory approval in Europe as it plans to fill with the European Medicines agency. Following regulatory approvals, Soleno Therapeutics Palms will launch the drug in the first quarter of 2026. Soleno Therapeutics is a biopharmaceutical company that develops and commercializes novel treatments for rare diseases. Their lead product, diazoxide choline extended-release tablets (DCCR), is being developed for Prader-Willi syndrome (PWS), specifically to address hyperphagia (excessive hunger). While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
